Should yellow fever vaccine be included in the expanded program of immunization in Africa ? A cost-effectiveness analysis for Nigeria.
The cost-effectiveness of preventive yellow fever vaccination versus emergency mass vaccination campaigns for epidemic control remains a matter of controversy.
Until recently, Nigeria and other anglophone countries in West Africa most severely afflicted by yellow fever epidemics have followed a policy of emergency control.
The effects of including yellow fever 17D vaccine in the Expanded Program of Immunization (EPI) on the immune status of the Nigerian population was studied under conservative assumptions ofvaccine coverage and efficacy.
The model defined the age-specific prevalence of immunity resulting from vaccination of infants and from natural endemic infection beginning in 1991 and extending over a time horizon of 35 years.
Mots-clés Pascal : Fièvre jaune, Arbovirose, Virose, Infection, Immunisation, Vaccination, Programme sanitaire, Coût financement, Homme, Nigéria, Afrique
Mots-clés Pascal anglais : Yellow fever, Arbovirus disease, Viral disease, Infection, Immunization, Vaccination, Sanitary program, Financing cost, Human, Nigeria, Africa
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 93-0382751
Code Inist : 002B05C02I1B. Création : 199406.